Atherogenic Index and High-Density Lipoprotein Cholesterol as Cardiovascular Risk Determinants in Rheumatoid Arthritis: The Impact of Therapy with Biologicals

• Published in: Mediators of Inflammation Vol. 2012; no. 2012; pp. 591 - 599-165
• Main Authors: van Riel, Piet L. C. M., Fransen, Jaap, Arts, Elke, Popa, Calin D.
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Limiteds 01.01.2012; Hindawi Publishing Corporation; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Animals; Arthritis, Rheumatoid - blood; Arthritis, Rheumatoid - complications; Arthritis, Rheumatoid - immunology; Arthritis, Rheumatoid - physiopathology; Cardiovascular diseases; Cardiovascular Diseases - blood; Cardiovascular Diseases - etiology; Cardiovascular Diseases - immunology; Cardiovascular Diseases - physiopathology; Care and treatment; Cholesterol, HDL; Cholesterol, HDL - blood; Complications and side effects; Health aspects; Humans; Inflammation - immunology; Inflammation - metabolism; Inflammation - physiopathology; Physiological aspects; Prevention; Review; Rheumatoid arthritis; Risk factors; Netherlands
• ISSN: 0962-9351; 1466-1861
• DOI: 10.1155/2012/785946

Cardiovascular (CV) diseases are a serious concern in rheumatoid arthritis (RA), accounting for approximately one-third to one-half of all RA-related deaths. Besides the attempts to identify new risk factors, the proper management of traditional CV risk factors such as dyslipidemia should become a priority in the periodic evaluation of every RA patient. Atherogenic index has been suggested to be less susceptible to disease activity variation during large periods of time, making him more attractive to be used in CV risk prediction in this group of patients as compared to individual lipids concentrations. Nevertheless, inflammation may negatively impact HDL antiatherogenic properties, suggesting that HDL function assessment is of particular importance when predicting CV risk in these patients. A tight control of inflammation becomes therefore crucial for a successful CV risk management. The present paper debates these hypotheses focusing on the effects of therapy with biologicals on the above mentioned parameters.